These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38229041)

  • 1. Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial.
    Abd Wahab HHB; O'Callaghan M
    BMC Urol; 2024 Jan; 24(1):16. PubMed ID: 38229041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
    JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials.
    Niu HL; Ma YH; Zhang CJ
    Int J Surg; 2018 Dec; 60():141-148. PubMed ID: 30415088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
    Komesu YM; Amundsen CL; Richter HE; Erickson SW; Ackenbom MF; Andy UU; Sung VW; Albo M; Gregory WT; Paraiso MF; Wallace D;
    Am J Obstet Gynecol; 2018 Jan; 218(1):111.e1-111.e9. PubMed ID: 29031894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
    Andy UU; Amundsen CL; Honeycutt E; Markland AD; Dunivan G; Dyer KY; Korbly NB; Bradley M; Vasavada S; Mazloomdoost D; Thomas S;
    Am J Obstet Gynecol; 2019 Nov; 221(5):513.e1-513.e15. PubMed ID: 31211964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
    Hendrickson WK; Zhang C; Jelovsek JE; Nygaard IE; Presson AP
    J Urol; 2024 Jan; 211(1):134-143. PubMed ID: 37871326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
    Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
    J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
    Richter HE; Amundsen CL; Erickson SW; Jelovsek JE; Komesu Y; Chermansky C; Harvie HS; Albo M; Myers D; Gregory WT; Wallace D;
    J Urol; 2017 Oct; 198(4):890-896. PubMed ID: 28501541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
    Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
    Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
    Shugg N; O'Callaghan ME
    BMC Urol; 2023 May; 23(1):98. PubMed ID: 37226116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
    Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis.
    Guirguis Hanna M; Bradley M; Zyczynski H; Wang L; Giugale L
    Neurourol Urodyn; 2023 Aug; 42(6):1238-1244. PubMed ID: 37086398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.
    Hendrickson WK; Xie G; Rahn DD; Amundsen CL; Hokanson JA; Bradley M; Smith AL; Sung VW; Visco AG; Luo S; Jelovsek JE
    Neurourol Urodyn; 2022 Jan; 41(1):432-447. PubMed ID: 34859485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
    Amundsen CL; Richter HE; Menefee S; Vasavada S; Rahn DD; Kenton K; Harvie HS; Wallace D; Meikle S
    Contemp Clin Trials; 2014 Mar; 37(2):272-83. PubMed ID: 24486637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for Nonneurogenic Urgency Incontinence.
    Hendrickson WK; Amundsen CL; Rahn DD; Meyer I; Bradley MS; Smith AL; Myers DL; Jelovsek JE; Lukacz ES
    Female Pelvic Med Reconstr Surg; 2021 Mar; 27(3):140-146. PubMed ID: 33620895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraoperative Predictors of Sacral Neuromodulation Implantation and Treatment Response: Results From the ROSETTA Trial.
    Gill BC; Thomas S; Barden L; Jelovsek JE; Meyer I; Chermansky C; Komesu YM; Menefee S; Myers D; Smith A; Mazloomdoost D; Amundsen CL
    J Urol; 2023 Aug; 210(2):331-340. PubMed ID: 37126070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Lowder J; Khandwala S; Sirls L; Spino C; Nolen TL; Wallace D; Meikle SF;
    N Engl J Med; 2012 Nov; 367(19):1803-13. PubMed ID: 23036134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.